Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Explore how Guident’s cutting-edge software is shaping the future of autonomous vehicles with CEO Harald Braun. Safety, control & AI at the wheel of innovation.
Wondercraft co-founder Oskar Serrander discusses the booming AI audio industry, deepfake risks, and the growing market for synthetic, AI-generated content.
Comerica’s Chief Economist Bill Adams unpacks U.S. retail sales, job growth, and the resurgence of market volatility—and what it all signals for the economy.
Saar Yoskovitz, CEO of Augury, shares how the company delivers AI infrastructure that Fortune 500s rely on to boost efficiency, reliability, and scale.
